BMY Bristol-Myers Squibb Company
Price (delayed)
$59.14
Market cap
$133.82B
P/E Ratio
92.41
Dividend/share
$1.76
EPS
$0.64
Enterprise value
$164.7B
Business Summary
Sector: Healthcare
Industry: Drug Manufacturers - General
Website: http://www.bms.com
Highlights
The company's revenue rose by 33% YoY and by 19% QoQ
Bristol Myers Squibb Co's gross profit has increased by 27% YoY and by 17% from the previous quarter
The quick ratio has decreased by 16% YoY but it has increased by 10% QoQ
The stock's price to earnings (P/E) is 154% more than its last 4 quarters average of 36.4 and 71% more than its 5-year quarterly average of 54.2
The net income has dropped by 82% year-on-year and by 72% since the previous quarter
Key stats
Shares outstanding
2.26B
Market cap
$133.82B
Enterprise value
$164.7B
EBIT
$2.67B
EBITDA
$6.72B
Price to earnings (P/E)
92.41
Price to book (P/B)
2.67
Price to sales (P/S)
4.31
EV/EBIT
61.76
EV/EBITDA
24.51
Net debt/EBITDA
4.6
EV/Sales
5.31
EBITDA margin
21.7%
Gross margin
68.1%
Net margin
3.1%
Operating margin
8.7%
Return on assets
1%
Return on equity
2.8%
Return on invested capital
5.8%
Return on capital employed
2.4%
Return on sales
8.6%
Debt to equity
0.94
Free cash flow
$9.75B
Free cash flow per share
$4.32
Book value per share
$22.11
Revenue per share
$13.73
TBVPS
$20.01
Current ratio
1.66
Quick ratio
1.38
Working capital
$12.62B
Dividend yield
2.98%
DPS
$1.76
Payout ratio
275%
BMY stock price
Financial performance
BMY's net margin has dropped by 86% year-on-year and by 77% since the previous quarter
The net income has dropped by 82% year-on-year and by 72% since the previous quarter
The operating margin has dropped by 67% year-on-year and by 54% since the previous quarter
The operating income has dropped by 56% year-on-year and by 46% since the previous quarter
Valuation
Price to earnings (P/E)
Price to book (P/B)
Price to sales (P/S)
Current price to earnings (P/E):
92.41
The stock's price to earnings (P/E) is 154% more than its last 4 quarters average of 36.4 and 71% more than its 5-year quarterly average of 54.2
Bristol Myers Squibb Co's EPS has shrunk by 80% YoY and by 68% QoQ
Current price to book (P/B):
2.67
BMY's P/B is 57% below its 5-year quarterly average of 6.2 and 24% below its last 4 quarters average of 3.5
Bristol Myers Squibb Co's equity has decreased by 3.3% from the previous quarter
Current price to sales (P/S):
4.31
The company's revenue rose by 33% YoY and by 19% QoQ
The price to sales (P/S) is 17% more than the last 4 quarters average of 3.7 but 10% less than the 5-year quarterly average of 4.8
Efficiency
Bristol Myers Squibb Co's ROA has plunged by 93% YoY and by 80% from the previous quarter
The ROE has plunged by 93% YoY and by 80% from the previous quarter
BMY's return on invested capital has dropped by 84% year-on-year and by 58% since the previous quarter
Bristol Myers Squibb Co's return on sales has shrunk by 67% YoY and by 55% QoQ
Dividends
DPS
$1.76
Dividend yield
2.98%
Payout ratio
275%
Recent dividends
Financial health
Assets vs liabilities
BMY's total assets is 63% greater than its total liabilities
The quick ratio has decreased by 16% YoY but it has increased by 10% QoQ
Bristol Myers Squibb Co's current ratio has decreased by 14% YoY but it has increased by 3.8% from the previous quarter
Debt vs equity
BMY's debt is 6% smaller than its equity
The company's debt to equity has surged by 135% YoY and by 3.3% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.